Department of Oncology, UNICANCER, Centre François Baclesse, Caen, France.
INSERM, U1086, Caen, France.
Psychooncology. 2022 Aug;31(8):1412-1419. doi: 10.1002/pon.5940. Epub 2022 May 13.
Art therapy (AT) as supportive care may help patients cope with cancer treatments. This non-blinded randomized trial assessed the impact of creative AT on severe fatigue and quality of life (QoL) in localized breast cancer patients undergoing irradiation.
320 patients were randomized to an AT group (ATG; 8 weekly sessions starting during irradiation) or to a standard group (SG). The primary endpoint was severe global fatigue (Functional Assessment of Chronic Therapy Fatigue subscale score <37) at 1 month post-irradiation. Quality of life (Fact-B), anxiety/depression (Hospital Anxiety and Depression Scale (HADS)) and different dimensions of fatigue 20-item Multidimensional Fatigue Inventory (MFI-20) were assessed at 1, 6 and 12 months post-irradiation. The secondary endpoints, fatigue among patients treated with chemotherapy, QoL (Fact-B), anxiety/depression (HADS) and different dimensions of fatigue (MFI-20) at 1, 6 and 12 months post-irradiation (with post hoc analysis in patients with treated with chemotherapy) were also assessed.
82% of patients completed ≥8 sessions. Severe initial global fatigue was observed in 43% of patients in each group, and among in 64% of patients whose treatment protocol contained chemotherapy. At 1 month post-irradiation, 45% in the ATG and 57% of patients in the SG reported severe global fatigue (p = 0.37); among patients with initial severe mental fatigue (MFF), 79% and 44% had improved MFF (p = 0.007) respectively; similarly 79% and 44% with initial poor motivation had better mental motivation (p = 0.03). At 6 and 12 months, social well-being scores in the ATG were higher (21.3 and 21.4 vs. 19.8 and 19.2, p = 0.05 and p < 0.01) with a significant improvement for patients who had chemotherapy (41% vs. 18%, p = 0.017). A positive association was observed between the number of AT sessions, fatigue and QoL (p < 0.01).
AT did not significantly improve global severe fatigue among all cancer participants 1 month after radiation therapy, however it had a positive impact on social well-being and may improve MFF and motivation.
艺术治疗（AT）作为支持性护理，可帮助癌症患者应对癌症治疗。本非盲随机试验评估了创意 AT 对接受放疗的局限性乳腺癌患者严重疲劳和生活质量（QoL）的影响。
320 名患者被随机分为艺术治疗组（ATG；在放疗期间开始的 8 次每周疗程）或标准组（SG）。主要终点为放疗后 1 个月时严重的全身疲劳（功能评估慢性治疗疲劳量表评分<37）。在放疗后 1、6 和 12 个月时评估生活质量（Fact-B）、焦虑/抑郁（医院焦虑和抑郁量表（HADS））和疲劳的不同维度（20 项多维疲劳量表（MFI-20））。还评估了放疗后 1、6 和 12 个月时接受化疗的患者的次要终点、疲劳、生活质量（Fact-B）、焦虑/抑郁（HADS）和疲劳的不同维度（MFI-20）（在接受化疗的患者中进行事后分析）。
82%的患者完成了≥8 次疗程。两组各有 43%的患者初始全身疲劳严重，64%的患者治疗方案中包含化疗。放疗后 1 个月，ATG 组有 45%的患者和 SG 组有 57%的患者报告全身疲劳严重（p=0.37）；在初始精神疲劳严重（MFF）的患者中，79%和 44%的患者 MFF 得到改善（p=0.007）；同样，79%和 44%初始动机不足的患者精神动机改善（p=0.03）。在 6 和 12 个月时，ATG 的社会福利评分较高（分别为 21.3 和 21.4 与 19.8 和 19.2，p=0.05 和 p<0.01），并且接受化疗的患者有显著改善（41%与 18%，p=0.017）。AT 疗程次数与疲劳和生活质量呈正相关（p<0.01）。
AT 并未显著改善所有癌症参与者放疗后 1 个月的全身严重疲劳，但对社会福利有积极影响，可能改善 MFF 和动机。
